Status: Recruiting
Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma
This study evaluates the feasibility of the combination of radiotherapy, chemotherapies (docetaxel, cisplatin and 5-fluorouracil) and spartalizumab (anti-PD-1 therapy) in patients with metastatic squamous cell anal carcinoma
Participants needed: 34
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Centre Hospitalier Universitaire de BesanconUpdated: Dec 22, 2023Locations: 5
Eligibility criteria
Male or female, aged ≥18 years, [+18]
HIV positive patient , CD4 count < 400 cells/mm3 (HIV test mandatory before incl... [+29]